An observational study in Acute Respiratory Disease, COPD Exacerbation Acute and Asthma, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by University of Leicester · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.
Among the 558 studies in Asthma with a site in United Kingdom, this one is the 35th largest by planned enrollment of the 131 observational ones that give a count, is one of 26 that started in 2022, is one of 131 observational ones, reaches primary completion later than 63 of the 70 other live ones, and was the 442nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
GlaxoSmithKline · Sites in United Kingdom, United States, Argentina and 1 more country
Ages 18+
University of Leeds · Sites in United Kingdom
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
558 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 132 · Phase 3 83 · Phase 4 50
First in 1991; this study’s year is marked. 26 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 69 across the 427 interventional studies, 149 across the 131 observational. Of the 445 that completed or were terminated, 155 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
320 of 558 have an industry lead sponsor. The 10 most frequent:
University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.
University of Leicester has 9 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
23 of the studies in Asthma with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT07833826University of NottinghamN-WATCH: Nottingham Wheeze Assessment in Tidal Children | 2026-12-31 |
| NCT07488897RIGImmune Inc.RIG 101 Trial in Healthy Adults and Adults With Asthma | 2027-02 |
Add all 23 to your calendar (.ics) → With an account.
Among the 558 studies in Asthma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the short- and long-term outcomes of people admitted to hospital with an acute respiratory condition, including exacerbations of chronic lung disease, and to understand factors that may predict recovery, hospital readmission, length of hospital stay, and mortality. A group of people with chronic respiratory disease who are being followed in respiratory outpatient clinics and a healthy control group without lung disease will also take part.
The main questions it aims to answer are:
Participants will undergo clinical assessments that may include questionnaires, measurements of physical function and muscle strength, lung function tests, physical activity monitoring, and collection of biological samples. Some participants may also undergo additional assessments of body composition, muscle size and function, imaging, or muscle metabolism, including through nested sub-studies. Participants will be followed for up to 36 months to assess recovery and longer-term clinical outcomes.
The study will recruit adults who are either admitted to hospital with an acute respiratory condition or are under the care of hospital respiratory outpatient services for a chronic respiratory disease. Acute respiratory presentations may include exacerbations of chronic lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, bronchiectasis and pleural disease, as well as acute respiratory illnesses including pneumonia, respiratory infection and pulmonary embolism. A separate healthy control group without underlying respiratory disease will also be recruited for comparison of selected exploratory measures.
Participants may be recruited during hospital admission or through respiratory outpatient services. Baseline assessments will be completed during hospitalisation or within 90 days of a routine clinical follow-up appointment, depending on the route of recruitment.
Participants recruited during an acute hospital admission may be invited to complete an early post-discharge assessment at approximately 30 days and up to three additional optional follow-up visits during the 12 months after discharge to assess clinical recovery. Participants recruited through respiratory outpatient services will be invited to undergo annual follow-up assessments. Follow-up for the main cohort will continue for up to 36 months, with permitted visit windows of up to 90 days.
Follow-up assessments may be completed by telephone, during a face-to-face research visit at the Biomedical Research Centre, during a research visit for another ethically approved study, or alongside routine clinical follow-up. Participants may choose not to attend further study visits after recruitment without affecting their usual clinical care.
If a participant is admitted to hospital during study follow-up, they may be invited to complete an additional assessment during the acute admission, within 7 days of hospitalisation, followed by up to three further assessments during the subsequent 12 months. Healthcare utilisation and clinical outcome data, including subsequent hospital admissions and treatments, may also be collected remotely from primary and secondary healthcare records.
Study assessments may include clinical characteristics, symptoms, health-related quality of life, frailty, sarcopenia, physical function, muscle strength, lung function, physical activity, body composition, muscle structure and function, physiological measurements, imaging and biological samples. These data will be used to characterise recovery following acute respiratory illness, investigate hospital-associated disability, explore potential biomarkers and develop approaches to risk stratification.
Healthy controls will undergo a baseline assessment only and will provide comparator data for selected exploratory outcomes.
MPES SUB-STUDY:
The Muscle Phenotyping Exploratory Study (MPES) is a sub-study nested within CHESTY and will be conducted at Glenfield Hospital. It is designed to provide more detailed assessment of skeletal muscle structure, function and metabolism using methods that complement the broader clinical phenotyping undertaken in the main CHESTY cohort.
The sub-study has two main aims. First, it will assess the feasibility, safety and tolerability of the additional muscle phenotyping methods, including high-density surface electromyography (EMG), ingested stable isotope tracer methodology and muscle biopsy procedures, in participants with respiratory disease and healthy volunteers. Second, it will use these methods exploratorily to undertake detailed skeletal muscle phenotyping, including assessment of muscle activation and neuromuscular function, skeletal muscle mass, muscle protein synthesis and muscle protein breakdown.
Up to 20 participants will be recruited to each of three groups: patients hospitalised with an acute exacerbation of COPD, patients with stable COPD, and age-comparable control participants without chronic respiratory disease. Participants may be recruited from existing CHESTY participants who have provided appropriate consent or through the same screening and recruitment pathways used for the main CHESTY study.
The MPES sub-study will use the same study site, research team and core assessments as CHESTY, including measures of physical function and muscle strength, questionnaires and muscle biopsy procedures where applicable.
Participants will include adults admitted to hospital with an acute respiratory condition, including exacerbations of an underlying physician-diagnosed chronic respiratory disease, as well as non-hospitalised patients under respiratory outpatient follow-up for a chronic respiratory condition. The study will also include healthy volunteers without chronic respiratory disease as a comparator group. Co-participation in other ethically approved studies, including interventional trials, is permitted.
Inclusion Criteria (Core study participants)
Exclusion Criteria (Core study participants)
Inclusion Criteria (Healthy Controls)
Exclusion Criteria (Healthy Controls)
Additional inclusion and exclusion criteria for CHESTY sub-studies are detailed in the corresponding sub-study protocols.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants admitted to hospital with an acute respiratory condition including exacerbation of an underlying physician diagnosed chronic lung disease.
The study will include matched controls (non-hospitalised patients with stable chronic respiratory conditions or healthy volunteers) to compare the exploratory endpoints. The number of the matched controls will not exceed 25% of the main study recruitment.
30 days hospital re-admission rate
To calculate the percentage of readmission due to the same acute respiratory illness within 30 days from consent
Time frame: 30 days
Length of index hospital admission stay
To calculate the length of the index hospital stay
Time frame: Variable (up to 52 weeks)
30 days mortality rate
To calculate the percentage of mortality within 30 days from consent
Time frame: 30 days
Total number of hospital readmission due to same underlying chronic lung disease.
To evaluate the number of hospital readmission episodes due to same underlying chronic lung disease over a 52 weeks period.
Time frame: 52 weeks
Total number of non-hospitalised exacerbations of underlying chronic lung disease
To evaluate the number of non-hospitalised exacerbations of chronic lung disease e.g. asthma, Chronic Obstructive Pulmonary Diseases (COPD), etc. over 52 weeks
Time frame: 52 weeks
Time from consent to death (respiratory causes and all causes)
To measure the time from consent to death within 52 weeks from consent. This will include both respiratory and all causes of mortality
Time frame: 52 weeks
Assessment of breathlessness using eMRC dyspnoea scale
To evaluate the degree of breathlessness at baseline and following recovery from acute respiratory illness using Extended MRC dyspnoea scale(eMRC). eMRC dyspnoea scale ranges from 1 to 5b with higher score indicates worse outcomes.
Time frame: 52 weeks
Assessment of quality of Life/symptoms using St. George's Respiratory Questionnaire (SGRQ)
St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: 52 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Feb 2022 (actual). Primary completion is estimated for Oct 2029, 92 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 92 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.